Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease.

Harigaya, Y; Shoji, M; Kawarabayashi, T; Kanai, M; Nakamura, T; Iizuka, T; Igeta, Y; Saido, T C; Sahara, N; Mori, H

Harigaya, Y; Shoji, M; Kawarabayashi, T; Kanai, M; Nakamura, T; Iizuka, T; Igeta, Y; Saido, T C; Sahara, N; Mori, H.

Affiliation

Harigaya Y; Department of Neurology, Gunma University School of Medicine, Japan.

Biochem Biophys Res Commun ; 211(3): 1015-22, 1995 Jun 26.

Article in En | MEDLINE | ID: mdl-7598687

Subject(s)

Alzheimer Disease; Amyloid beta-Peptides/chemistry; Aged; Aged, 80 and over; Amyloid beta-Peptides/immunology; Antibodies, Monoclonal; Antibody Specificity; Brain Chemistry; Fluoroimmunoassay; Humans; Immunoblotting

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Amyloid beta-Peptides / Alzheimer Disease Limits: Aged / Aged80 / Humans Language: En Journal: Biochem Biophys Res Commun Year: 1995 Document type: Article Affiliation country: Japan Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links